Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04604275 · ClinicalTrials.gov registry record · Phase 2
Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure
A Phase 2 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04604275 is a Phase 2 study that was terminated before completion, run by University of Miami. The registered enrollment target is 3 participants.
The verdict
NCT04604275, a Phase 2 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Short gut syndrome with intestinal failure patients may have decreased production of disaccharidases, like sucrase, an enzyme responsible for digesting sugar in foods. This can happen due to loss of bowel length from surgery or from loss of cellular function in the intestines due to use of parenteral nutrition intravenously. Therefore, patients with these conditions may not be able to digest sucrose (sugar) fully. Patients might experience abdominal distension/pain, vomiting and diarrhea when sugar is taken in orally or through the g-tube, which can limit patients' ability to increase oral or g-tube feeds in short gut syndrome patients with intestinal failure. In patients with short gut syndrome and intestinal failure, the administration of exogenous sucrase (enzyme) may improve sucrose (sugar) digestion and thus the ability to tolerate more oral or g-tube feeds.
Interventions
- OTHER Placebo
- DRUG Sucrase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2024-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04604275
The ClinicalTrials.gov registry entry for NCT04604275 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04604275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04604275 about?
NCT04604275 is a clinical study titled "Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure". Short gut syndrome with intestinal failure patients may have decreased production of disaccharidases, like sucrase, an enzyme responsible for digesting sugar in foods. This can happen due to loss of bowel length from surgery or from loss of cellular function in the intestines due to use of parentera...
What is the current status of trial NCT04604275?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-01-31. Estimated completion is 2024-09-01.
What interventions are being tested in trial NCT04604275?
The interventions under investigation include: Placebo (OTHER), Sucrase (DRUG).
Who is sponsoring clinical trial NCT04604275?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.